CStone Pharmaceuticals
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junctio… Read more
CStone Pharmaceuticals - Asset Resilience Ratio
CStone Pharmaceuticals (CSPHF) has an Asset Resilience Ratio of 16.36% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how CStone Pharmaceuticals's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down CStone Pharmaceuticals's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $195.00 Million | 16.36% |
| Total Liquid Assets | $195.00 Million | 16.36% |
Asset Resilience Insights
- Good Liquidity Position: CStone Pharmaceuticals maintains a healthy 16.36% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
CStone Pharmaceuticals Industry Peers by Asset Resilience Ratio
Compare CStone Pharmaceuticals's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for CStone Pharmaceuticals (2016–2024)
The table below shows the annual Asset Resilience Ratio data for CStone Pharmaceuticals.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 20.45% | $285.00 Million | $1.39 Billion | +17.33pp |
| 2023-12-31 | 3.12% | $51.85 Million | $1.66 Billion | -26.38pp |
| 2022-12-31 | 29.50% | $483.41 Million | $1.64 Billion | -13.80pp |
| 2021-12-31 | 43.30% | $983.62 Million | $2.27 Billion | +33.50pp |
| 2020-12-31 | 9.81% | $369.00 Million | $3.76 Billion | -44.97pp |
| 2019-12-31 | 54.77% | $1.62 Billion | $2.95 Billion | +2.29pp |
| 2018-12-31 | 52.49% | $856.63 Million | $1.63 Billion | -28.02pp |
| 2017-12-31 | 80.51% | $454.30 Million | $564.28 Million | -10.56pp |
| 2016-12-31 | 91.07% | $752.39 Million | $826.14 Million | -- |